Type of security: Stock
Sector: Health Care
Industry: Biotechnology: Biological Products (No Diagnostic Substances)
The data is delayed by 15 minutes.
Description: Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops gene therapy products for inherited orphan ophthalmology diseases in the United States. The company?s lead product candidates in the preclinical stage comprise treatments for X-linked retinoschisis, Congenital Achromatopsia, and X-linked retinitis pigmentosa, which are diseases of the eye caused by mutations in single genes. It also has completed preclinical proof-of-concept studies, and Phase I and Phase II clinical trials of a treatment for alpha-1 antitrypsin deficiency, an inherited orphan lung disease. In addition, the company has proof-of-concept programs for other eye diseases, such as leber congenital amaurosis (type 2), and wet form of age-related macular degeneration. It has strategic collaboration agreements with SAFC Pharma. The company was founded in 1999 and is headquartered in Alachua, Florida.
|Shares Outstanding||EPS||0.41||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||129.03%||Sales Growth - Q/Q||-56.44%||P/E||12.32|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-21.62%||ROE||-22.5%||ROI|
|Current Ratio||17.17||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.04|
|Gross Margin||Operating Margin||-1185.67%||Net Profit Margin||-1182.89%||Dividend Payout Ratio|
|Cash From Financing Activities||32.16 M||Cash From Investing Activities||16.78 M||Cash From Operating Activities||-13.08 M||Gross Profit|
|Net Profit||-6.33 M||Operating Profit||-6.39 M||Total Assets||96.58 M||Total Current Assets||65.11 M|
|Total Current Liabilities||3.79 M||Total Debt||Total Liabilities||3.79 M||Total Revenue||280 K|
|High 52 week||10.05||Low 52 week||3.4||Last close||4.2||Last change||-2.33%|
|RSI||67.86||Average true range||0.21||Beta||1.51||Volume||53.6 K|
|Simple moving average 20 days||8.53%||Simple moving average 50 days||10.66%||Simple moving average 200 days||-9.89%|
|Performance Week||-2.33%||Performance Month||16.67%||Performance Quart||7.69%||Performance Half||-14.29%|
|Performance Year||-54.59%||Performance Year-to-date||16.67%||Volatility daily||2.87%||Volatility weekly||6.41%|
|Volatility monthly||13.14%||Volatility yearly||45.51%||Relative Volume||237.74%||Average Volume||104.71 K|
|New High||New Low|
2020-05-26 10:50:02 | Why Applied Genetic Technologies AGTC Stock Might be a Great Pick
2020-05-25 12:00:04 | Applied Genetic Technologies AGTC Upgraded to Strong Buy: Here's What You Should Know
2020-05-25 11:30:03 | Is Applied Genetic Technologies AGTC Outperforming Other Medical Stocks This Year?
2020-05-20 07:00:10 | AGTC Announces Publication of Positive Preclinical Data that Provides Foundational Scientific Evidence for its Ongoing Clinical Program in Patients with X-Linked Retinitis Pigmentosa XLRP
2020-05-15 06:24:59 | Is Applied Genetic Technologies NASDAQ:AGTC In A Good Position To Invest In Growth?
2020-05-14 00:49:17 | Edited Transcript of AGTC earnings conference call or presentation 13-May-20 12:00pm GMT
2020-05-13 10:45:02 | Applied Genetic Technologies AGTC Reports Q3 Loss, Misses Revenue Estimates
2020-05-13 08:25:12 | Applied Genetic Technologies' Shares March Higher, Can It Continue?
2020-05-06 07:00:10 | AGTC to Host Third Quarter Financial Results Conference Call and Webcast on May 13, 2020
2020-04-28 12:34:04 | Earnings Preview: Applied Genetic Technologies AGTC Q3 Earnings Expected to Decline
2020-04-22 07:20:11 | Applied Genetic Technologies' Shares March Higher, Can It Continue?
2020-03-24 12:00:04 | All You Need to Know About Applied Genetic Technologies AGTC Rating Upgrade to Buy
2020-02-16 08:50:08 | 2 “Strong Buy” Healthcare Stocks with Over 100% Upside Potential
2020-02-06 20:06:24 | AGTC Announces Pricing of $32,500,000 Public Offering of Common Stock
2020-02-05 16:36:58 | AGTC Announces Proposed Public Offering of Common Stock
2020-01-22 16:01:10 | AGTC to Host Conference Call and Webcast on January 23 at 8:00 am ET to Discuss Achromatopsia Interim Six-Month Data from the Dose Escalation Cohorts of its Ongoing CNGB3 and CNGA3 Phase 1/2 Clinical Trials
2020-01-21 07:00:10 | AGTC Announces Agenda for R&D Day on January 28, 2020 in New York
2020-01-10 10:08:03 | Applied Genetic Stock Up on Favorable Eye Therapy Study Data
2020-01-10 09:08:02 | Company News for Jan 10, 2020
2020-01-10 09:07:02 | Implied Volatility Surging for Applied Genetic Technologies AGTC Stock Options
2020-01-10 07:13:12 | The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx
2020-01-09 10:02:47 | Applied Genetic Shares Rip Higher After Eye Disorder Gene Therapy Aces Midstage Trial
2020-01-09 08:34:00 | Applied Genetic Technologies' stock rockets on early-stage eye therapy data
2020-01-08 16:01:10 | AGTC to Host Conference Call and Webcast on January 9 at 8:00 am ET to Discuss X-Linked Retinitis Pigmentosa Interim Six-Month Data from the Dose Expansion Cohort of its Ongoing Phase 1/2 Clinical Trial
2019-12-19 09:17:00 | Biotech Stocks Are In a Position to Break Out in 2020, Analysts Say
2019-12-17 19:36:43 | Is Applied Genetic Technologies Corp AGTC A Good Stock To Buy?
2019-11-13 12:34:48 | Edited Transcript of AGTC earnings conference call or presentation 12-Nov-19 9:30pm GMT
2019-11-12 17:55:10 | Applied Genetic Technologies AGTC Reports Q1 Loss, Lags Revenue Estimates
2019-11-06 07:00:00 | AGTC to Host First Quarter Results Conference Call and Webcast on November 12, 2019
2019-10-31 06:38:19 | We Think Applied Genetic Technologies NASDAQ:AGTC Can Afford To Drive Business Growth
2019-09-30 12:03:32 | Applied Genetic Notches Sell-Side Upgrade After Releasing Interim Study Data
2019-09-27 19:59:26 | Edited Transcript of AGTC earnings conference call or presentation 26-Sep-19 8:30pm GMT
2019-09-26 17:35:09 | Applied Genetic Technologies AGTC Reports Q4 Loss, Lags Revenue Estimates